237 results about "Nerve Diseases" patented technology

The present invention provides a system for providing neurological disease state information to a patient. The system comprises one or more sensors that sense at least one signal that comprise feature(s) that are indicative of a neurological disease state. A signal processing assembly is in communication with the one or more sensors and processes the at least one signal to estimate the neurological disease state. A patient interface module is in communication with the signal processing assembly and communicates with a patient an output that is indicative of the patient's estimated neurological disease state.

The present invention provides objective methods of diagnosis and behavioural treatments of neurological disorders such as autism spectral disorders and Parkinson's disease.

The present invention discloses compositions and methods for enhancing the effect (e.g., duration) of a neurotoxin treatment. The compositions herein include neurotoxins and neuron growth inhibitors. Such compositions are administered locally to treat or prevent conditions, such as dermatological conditions, urological conditions, thyroid conditions, optical conditions, and neurological conditions.

The present invention relates to methods and devices for noninvasive nonlinear prediction of ictal onset in patients afflicted by neurological disease. In particular, the present invention provides methods and devices for noninvasive nonlinear prediction of seizures in patients afflicted with epilepsy. The devices and methods preferably being based on analysis of two or more electroencephalogram (EEG) recordings, one set of recordings taken from an electrode close to the region of ictal onset, and a second or more set of recordings (e.g., concurrent readings) taken from a region remote from the region of ictal onset.

Methods of treating certain neurological diseases using exogenous uridine or a uridine source alone as a precursor of endogenous cytidine, particularly in the human brain, are disclosed. Methods are also disclosed wherein exogenous uridine or a uridine source is combined either with drugs increasing uridine availability or with compounds that serve as a source of choline in phospholipid synthesis.

The present invention relates to methods for modulating progestagen signaling for treating neurological disorders or neurodegenerative disease, or preventing or delaying its onset in individuals deemed by competent observation and testing to be susceptible thereto. Progestagens can be administered to elevate serum and brain levels of progestagens and induce neurogenesis. Progestagen therapy may prevent some of the neurodegenerative and cognitive changes associated with developmental and aging associated neurological disorders and neurodegenerative diseases. Progestagen therapy together with suppression of GnRH, kisspeptin, LH and/or FSH signaling also may be used for treating neurological disorders or neurodegenerative diseases. The invention also relates to methods for inhibiting or delaying blastulation during embryogenesis, and neurogenesis during embryogenesis, fetal, neonatal, childhood, puberty or adult life. Blocking progestagen, estrogen and/or opioid signaling with receptor antagonists will inhibit neurogenesis. The invention also relates to using progestagens in vitro to induce neurogenesis in embryonic or adult stem cells.

The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.

This invention relates to human adipose tissue-derived multipotent adult stem cells. More particularly, the invention relates to human adipose tissue-derived multipotent stem cells, which can be maintained in an undifferentiated state for a long period of time by forming spheres and have high proliferation rates, as well as methods for isolating and maintaining the adult stem cells, and methods for differentiating the multipotent adult stem cells into nerve cells, fat cells, cartilage cells, osteogenic cells and insulin-releasing pancreatic beta-cells. Also, the invention relates to cellular therapeutic agents for treating osteoarthritis, osteoporosis and diabetes and for forming breast tissue, which contain the differentiated cells or the adult stem cells. Although the multipotent stem cells are adult stem cells, they have the ability to differentiate into osteogenic cells, nerve cells, astrocytes, fat cells, chrondrogenic cells or insulin-releasing pancreatic beta-cells, and so are effective in treating osteoporosis, osteoarthritis, nerve disease, diabetes, etc. Also, the stem cells form spheres in a serum-free medium containing CORM-2, and thus can be maintained in an undifferentiated state for a long period of time. Also, the stem cells have very high proliferation rates. Accordingly, the stem cells are useful as cellular therapeutic agents.

Provided herein are methods and uses for treatment or prophylaxis of a senescent cell associated disease or disorder by administering a senolytic combination comprising dasatinib and quercetin or an analog thereof to a subject in need thereof. In certain embodiments, the senescent cell associated disease or disorder is a cardiovascular disease or disorder, inflammatory disease or disorder, a pulmonary disease or disorder, a neurological disease or disorder, or a metabolic disease or disorder.

The invention concerns pharmaceutical compositions that contain a compound or compounds that can effectively regulate the activity of Type 5 Adenylyl Cyclase and methods for treatment of neurological diseases and disorders, as well as motor function loss therefrom, as well as treatment for cardiac conditions and diseases including conditions characterized by abnormal heart rate.

The disclosure provides an apparatus and method for assessing brain plasticity by measuring electrical brain biomarkers, for example, with a near real-time analysis of electrical brain biomarkers, where an increase or decrease in at least one biomarker is indicative of a state of brain plasticity in response to a stimulus or treatment. Brain plasticity can be measured with or without an added stimuli, for example, to determine the best time for learning. Also provided is a method for treating a neurological disease or trauma by applying an electrical or drug stimulus to a patient, where the stimulus is increased or decreased depending on the changes of electrical brain biomarker of the patient. This treatment can occur in near real-time, so a course of treatment can be tailored immediately to a patient's needs.

The invention relates to substituted sulphonamide compound and preparation method, medicine composition and application thereof, in particular provides the substituted sulphonamide compound shown in general formula (I) or pharmaceutically acceptable salt thereof, Ar, X, Y, Z and R are defined in the specification. The compound has good preventing and treating effect on diseases mediated by GPR40 such as diabetes, breast cancer and certain nerve disease. The compound is GTP bonding protein ion-channel-linked receptor 40 antagonist. Thus, the compound is hopeful to be developed into novel medicine for treating diabetes and the like. The invention also provides the preparation method and medicine composition of the compound.

Detection of neurological diseases such as Parkinson's disease can be accomplished through analyzing a subject's speech for acoustic measures based on human factor cepstral coefficients (HFCC). Upon receiving a speech sample from a subject, a signal analysis can be performed that includes identifying articulation range and articulation rate using HFCC and delta coefficients. A likelihood of Parkinson's disease, for example, can be determined based upon the identified articulation range and articulation rate of the speech.

Methods for identifying networks correlating with placebo effects, progression of neurological disease symptoms, progression of pre-phenoconversion states of neurological diseases, and efficacious/non-efficacious candidate treatments for neurological diseases are provided.

The invention relates to a preparation method for a cyclopropylamine spiro(hetero)cyclic compound and a composition containing the same, and application of the compound and the composition as an inhibitor for human lysine-specific demethylase (LSD1). The inhibitor is the cyclopropylamine spiro(hetero)cyclic compound as shown in a formula (I) which is described in the specification, or a pharmaceutically acceptable salt, predrug, solvate, polymorphic crystal or stable isotope derivative thereof. The compound can be used for treating or preventing diseases related to human lysine-specific demethylase, e.g., cancers and nerve diseases.

The present invention relates to a method of inhibiting differentiation of a population of neural stem cells by contacting a purinergic receptor agonist and a population of neural stem cells under conditions effective to inhibit differentiation of the population of neural stem cells. Another aspect of the present invention relates to a method of producing neurons and/or glial cells from a population of neural stem cells by culturing a population of neural stem cells with a purinergic receptor antagonist under conditions effective to cause the neural stem cells to differentiate into neurons and/or glial cells. The purinergic receptor agonist can also be used in a method of inducing proliferation and self-renewal of neural stem cells in a subject and a method of treating a neurological disease or neurodegenerative condition in a subject. The purinergic receptor antagonist can also be used in treating a neoplastic disease of the brain or spinal cord in a subject.

The invention provides methods for treating or preventing cardiac and neurological disorders using chemokine receptor antagonists.